The research interests of Michael D. Leise, M.D., pertain to the treatment and outcomes of hepatitis C, the diagnosis and treatment of hepatic encephalopathy, and liver transplant outcomes.
With the advent of direct-acting antiviral therapy, new research questions have arisen with regard to real-world treatment outcomes, viral resistance and effects on patients with concomitant hepatocellular carcinoma. These clinically relevant questions are being evaluated by Dr. Leise and collaborators across the three Mayo Clinic campuses.
Hepatic encephalopathy is common and has a significant impact on the lives of patients with this condition, and their caregivers. Dr. Leise is interested in novel markers for prediction, diagnosis and new methods to manage this hepatic encephalopathy.
Liver transplantation provides excellent outcomes for carefully selected patients, yet the demand far exceeds the supply of donor organs. Dr. Leise is interested in liver transplant research related to epidemiology, trends and outcomes.
- Novel treatment modalities for hepatic encephalopathy
- Real-world effectiveness in the treatment of hepatitis C
- Liver transplant outcomes
Significance to patient care
Through his research, Dr. Leise hopes to individualize treatment for patients with hepatitis C, provide novel treatment strategies for those with hepatic encephalopathy, and improve liver transplant outcomes.
- Recipient, Bristol-Myers Squibb Virology Fellows Research Program Grant, 2009-2010
- Recipient, Career Development Award, Clinical and Translational Science Awards Program, 2012-2013
- Recipient, Career Development Award, Mayo Clinic Department of Medicine, 2012-2013
- Recipient, Scholarly Clinician Award, Mayo Clinic Transplant Center, 2014-2016